M&T Bank Corp Purchases 231,620 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• M&T Bank Corp boosted its stake in Arrowhead Pharmaceuticals by 2,569.6% in Q4, buying 231,620 shares to hold 240,634 shares (about 0.18% of the company) valued at roughly $15.98 million.
• Insider James C. Hamilton sold 10,000 shares on March 5 at an average price of $64.19 for $641,900, trimming his position by about 4.05%; company insiders now own 3.60% of the stock.
• Arrowhead trades near $74.40 with a $10.42 billion market cap and has an analyst consensus of "Moderate Buy" and a $83.78 target, despite a quarterly EPS miss ($0.22 vs. $0.60) alongside a large year-over-year revenue increase to $264.03 million.

M&T Bank Corp increased its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 2,569.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 240,634 shares of the biotechnology company's stock after purchasing an additional 231,620 shares during the period. M&T Bank Corp owned approximately 0.18% of Arrowhead Pharmaceuticals worth $15,976,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ARWR. iSAM Funds UK Ltd bought a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $29,000. First Horizon Corp bought a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $32,000. Salomon & Ludwin LLC bought a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $34,000. Federated Hermes Inc. bought a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $52,000. Finally, Smartleaf Asset Management LLC lifted its position in Arrowhead Pharmaceuticals by 2,186.5% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company's stock valued at $57,000 after acquiring an additional 1,618 shares in the last quarter. 62.61% of the stock is owned by institutional investors.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 10,000 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $64.19, for a total value of $641,900.00. Following the transaction, the insider owned 236,958 shares in the company, valued at $15,210,334.02. This represents a 4.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.60% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Price Performance

NASDAQ ARWR opened at $74.40 on Friday. The business's fifty day moving average price is $62.63 and its 200-day moving average price is $57.95. The stock has a market capitalization of $10.42 billion, a price-to-earnings ratio of 48.63 and a beta of 1.26. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.38 and a quick ratio of 3.38. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $12.44 and a 1-year high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The firm had revenue of $264.03 million for the quarter, compared to the consensus estimate of $225.66 million. During the same period in the previous year, the company earned ($1.39) earnings per share. Arrowhead Pharmaceuticals's quarterly revenue was up 10461.3% compared to the same quarter last year. On average, equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.37 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. The Goldman Sachs Group upped their price objective on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a "neutral" rating in a research report on Wednesday, January 7th. Chardan Capital upped their target price on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a "buy" rating in a research note on Wednesday, January 7th. HC Wainwright restated a "buy" rating and set a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, March 25th. Weiss Ratings upgraded shares of Arrowhead Pharmaceuticals from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Friday, February 6th. Finally, B. Riley Financial upped their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a "buy" rating in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $83.78.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.